PERSEUS MRD Analysis
Phase III PERSEUS: MRD Analysis of VRd ± Daratumumab in Newly Diagnosed Multiple Myeloma Eligible for ASCT

Released: June 07, 2024

Expiration: June 06, 2025

Activity

Progress
1
Course Completed